Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 7, 2009, Pages 2207-2212

  Cozzolino, Mario ^a   Biondi, Maria Luisa ^b   Galassi, Andrea ^a   Turri, Olivia ^b   Brancaccio, Diego ^a,c   Gallieni, Maurizio ^a,c  

^a Renal Division   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Genetic polymorphism; Haemodialysis; Metalloproteinases

Indexed keywords

INTERSTITIAL COLLAGENASE; STROMELYSIN;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS PATIENT; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGED; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RENAL DIALYSIS;

EID: 67651121914     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp061     Document Type: Article

References (36)

1. Foley RN, Parfrey PS. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119
2. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362
3. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002; 13: 1918-1927
4. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003; 14: S305-S309
5. Cozzolino M, Brancaccio D, Gallieni M et al. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436
6. Cozzolino M, Mazzaferro S, Pugliese F et al. Vascular calcification and uremia: what do we know? Am J Nephrol 2008; 28: 339-346
7. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-878
8. Nikkari ST, O'Brian KD, Ferguson M et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398
9. Ye S, Watts GF, Mandalia S et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-215
10. Ye S, Eriksson P, Hamsten A et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. JBiolChem 1996; 271: 13055-13060
11. Ghilardi G, Biondi ML, DeMonti M et al. Matrix metalloproteinase- 1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408-2412
12. Pearce E, Tregouet DA, Samnegård A et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res 2005; 97: 1070-1076
13. Newby AC, Johnson JL. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res 2005; 97: 958-960
14. Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. JMedGenet 2006; 43: 897-901
15. Birkedal-Hansen H, Moore WG, Bodden MK et al. Matrix metalloproteinases: a review. CritRevOralBiolMed 1993; 4: 197-250
16. Humphries SE, Luong LA, Talmud PJ et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998; 139: 49-56
17. Hirashiki A, Yamada Y, Murase Y et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 2003; 42: 1429-1437
18. Schwarz A, Haberbosch W, Tillmanns H et al. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis Markers 2002; 18: 121-128
19. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850
20. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-2020
21. Henney AM, Wakeley PR, Davies MJ et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991; 88: 8154-8158
22. Galis ZS, Sukhova GK, Lark MW et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503
23. Terashima M, Akita H, Kanazawa K et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-2719
24. Nojiri T, Morita H, Imai Y et al. Genetic variations of matrix metalloproteinase-1 and-3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003; 92: 181-186
25. Liu PY, Chen JH, Li YH et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003; 90: 132-139
26. Zhou X, Huang J, Chen J et al. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb Haemost 2004; 92: 867-873
27. McGlinchey PG, Spence MS, Patterson CC et al. The matrix metalloproteinase-3 (MMP-3) 5A/6A promoter polymorphism is not associated with ischaemic heart disease: analysis employing a family based approach. Dis Markers 2004; 20: 289-294
28. Cozzolino M, Dusso AS, Slatopolsky E. Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511-2516
29. Bini A, Mann KG, Kudryk BJ et al. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 1852-1861
30. Pollanen PJ, Lehtimaki T, Ilveskoski E et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase: 3. The Helsinki Sudden Death Study. Atherosclerosis 2002; 164: 329-335
31. Gnasso A, Motti C, Irace C et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600-1605
32. Rauramaa R, Vaisanen SB, Luong LA et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-2662
33. Rundek T, Elkind MS, Pittman J et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33: 1420-1423
34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
35. Cozzolino M, Biondi ML, Galassi A et al. Gene polymorphisms and serum alpha-2-heremans-schmid levels in Italian haemodialysis patients. Am J Nephrol 2007; 27: 639-642
36. Brancaccio D, Biondi ML, Gallieni M et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 2005; 25: 548-552